Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

BACKGROUND: Prospective evidence is lacking regarding incremental benefits of long-acting dual- versus mono-bronchodilation in improving symptoms and preventing short-term disease worsening/treatment failure in low exacerbation risk patients with chronic obstructive pulmonary disease (COPD) not rece...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Respir Res
Glavni autori: Maltais, François, Bjermer, Leif, Kerwin, Edward M., Jones, Paul W., Watkins, Michael L., Tombs, Lee, Naya, Ian P., Boucot, Isabelle H., Lipson, David A., Compton, Chris, Vahdati-Bolouri, Mitra, Vogelmeier, Claus F.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821007/
https://ncbi.nlm.nih.gov/pubmed/31666084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-019-1193-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items